KR101077689B1 - 허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드 - Google Patents

허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드 Download PDF

Info

Publication number
KR101077689B1
KR101077689B1 KR1020057015480A KR20057015480A KR101077689B1 KR 101077689 B1 KR101077689 B1 KR 101077689B1 KR 1020057015480 A KR1020057015480 A KR 1020057015480A KR 20057015480 A KR20057015480 A KR 20057015480A KR 101077689 B1 KR101077689 B1 KR 101077689B1
Authority
KR
South Korea
Prior art keywords
prtp801
vegf
seq
plasmid
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057015480A
Other languages
English (en)
Korean (ko)
Other versions
KR20050103302A (ko
Inventor
민형 이
성완 김
Original Assignee
유니버시티 오브 유타 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리써치 파운데이션 filed Critical 유니버시티 오브 유타 리써치 파운데이션
Publication of KR20050103302A publication Critical patent/KR20050103302A/ko
Application granted granted Critical
Publication of KR101077689B1 publication Critical patent/KR101077689B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020057015480A 2003-02-21 2004-02-23 허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드 Expired - Fee Related KR101077689B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44896103P 2003-02-21 2003-02-21
US60/448,961 2003-02-21

Publications (2)

Publication Number Publication Date
KR20050103302A KR20050103302A (ko) 2005-10-28
KR101077689B1 true KR101077689B1 (ko) 2011-10-27

Family

ID=32927484

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057015480A Expired - Fee Related KR101077689B1 (ko) 2003-02-21 2004-02-23 허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드

Country Status (9)

Country Link
US (2) US7638322B2 (enExample)
EP (1) EP1594549B1 (enExample)
JP (1) JP4652325B2 (enExample)
KR (1) KR101077689B1 (enExample)
AT (1) ATE456380T1 (enExample)
CA (1) CA2516727C (enExample)
DE (1) DE602004025328D1 (enExample)
ES (1) ES2339113T3 (enExample)
WO (1) WO2004076633A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002043A (es) 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
NL2000439C2 (nl) 2006-01-20 2009-03-16 Quark Biotech Therapeutische toepassingen van inhibitoren van RTP801.
GB2450840B (en) 2006-05-11 2010-12-29 Quark Pharmaceuticals Inc Screening Systems Utilizing RTP801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
EP2137205A2 (en) 2007-02-26 2009-12-30 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6548633B1 (en) * 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, Vol. 99(14) pp.9480-9485 (2002)

Also Published As

Publication number Publication date
US7638322B2 (en) 2009-12-29
WO2004076633A3 (en) 2005-06-02
CA2516727A1 (en) 2004-09-10
US7998941B2 (en) 2011-08-16
JP4652325B2 (ja) 2011-03-16
CA2516727C (en) 2014-02-04
EP1594549A4 (en) 2008-01-23
DE602004025328D1 (de) 2010-03-18
JP2006518604A (ja) 2006-08-17
KR20050103302A (ko) 2005-10-28
EP1594549A2 (en) 2005-11-16
EP1594549B1 (en) 2010-01-27
ATE456380T1 (de) 2010-02-15
US20110015257A1 (en) 2011-01-20
US20070149467A1 (en) 2007-06-28
ES2339113T3 (es) 2010-05-17
WO2004076633A2 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
RU2718248C2 (ru) Аденоассоциированные вирусные векторы для лечения лизосомных болезней накопления
CN110835633B (zh) 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用
JP2024041819A (ja) 合成ｄｎａベクターおよびその使用
KR20220149588A (ko) 대사성 간 장애의 치료를 위한 조성물 및 방법
KR20210148227A (ko) 재조합 바이러스 벡터의 제조 방법
CN1997745A (zh) 癌症特异性启动子
KR101077689B1 (ko) 허혈성 질환용 저산소상태 유도성 혈관 내피 성장 인자플라스미드
KR20110126586A (ko) 단일 재조합 계 및 그의 사용 방법
CN112852860B (zh) 质粒载体及其在构建多拷贝表达系统中的应用
CN107541526B (zh) 能敲低内源性ctla4表达的cik及制备方法与应用
KR20210137427A (ko) Car t 세포 방법 및 작제물
CN109055425B (zh) 一种带有黄色或红色荧光蛋白标签的非洲爪蟾卵母细胞表达载体及应用
CA2677475C (en) Expression of polypeptides from the nuclear genome of ostreococcus sp
KR102065917B1 (ko) Glb1 유전자를 발현하는 형질전환된 줄기세포 및 이를 포함하는 gm1 강글리오시드증 치료용 약학 조성물
CN107287239B (zh) 一种用于视网膜色素变性的基因治疗载体及药物
CN109402155A (zh) 一种双控延迟裂解性质粒及其构建方法与应用
KR102283918B1 (ko) 인간인슐린유사성장인자 타입1 (hIGF1) 생산 발현용 벡터 및 상기 벡터로 형질전환된 미세조류
CN111471665B (zh) 一种dna环化分子及其用途
CN117597352A (zh) 基于微球菌素的羧酸化合物的制备方法和由此制备的基于微球菌素的羧酸化合物
CN111909918B (zh) 一种内溶素突变体及其编码基因与应用
KR102226252B1 (ko) 리소좀을 포함하는 미백용 조성물
KR102283915B1 (ko) 인간섬유아세포성장인자 타입1 (hFGF1) 생산 발현용 벡터 및 상기 벡터로 형질전환된 미세조류
KR20230145148A (ko) 망막 질환에 대한 유전자 요법
KR102273945B1 (ko) 인간섬유아세포성장인자 타입2 (hFGF2) 생산 발현용 벡터 및 상기 벡터로 형질전환된 미세조류
CN106566844B (zh) 一种下调真核基因表达的方法及其试剂盒

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20141022

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20141022